What is Zacks Research’s Forecast for RDY FY2027 Earnings?

Dr. Reddy’s Laboratories Ltd (NYSE:RDY) – Investment analysts at Zacks Research lifted their FY2027 earnings per share (EPS) estimates for Dr. Reddy’s Laboratories in a research report issued on Friday, November 6th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $0.44 for the year, up from their prior forecast of $0.43. The consensus estimate for Dr. Reddy’s Laboratories’ current full-year earnings is $0.46 per share. Zacks Research also issued estimates for Dr. Reddy’s Laboratories’ Q4 2027 earnings at $0.10 EPS, Q3 2028 earnings at $0.15 EPS, Q4 2028 earnings at $0.14 EPS, FY2028 earnings at $0.53 EPS and FY2029 earnings at $0.65 EPS.

RDY has been the subject of a number of other reports. Wall Street Zen upgraded shares of Dr. Reddy’s Laboratories from a “sell” rating to a “hold” rating in a report on Saturday, October 17th. JPMorgan Chase & Co. raised shares of Dr. Reddy’s Laboratories from an “underweight” rating to a “neutral” rating in a research note on Monday, October 26th. BNP Paribas Exane raised shares of Dr. Reddy’s Laboratories to an “outperform” rating and set a $14.80 price objective on the stock in a research note on Monday, October 12th. Jefferies Financial Group upgraded shares of Dr. Reddy’s Laboratories from an “underperform” rating to a “hold” rating and set a $13.90 target price on the stock in a research report on Sunday, October 25th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Dr. Reddy’s Laboratories in a research note on Wednesday, October 21st. Two equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $492.90.

Dr. Reddy’s Laboratories Price Performance

NYSE:RDY opened at $15.03 on Monday. The firm has a market cap of $12.55 billion, a price-to-earnings ratio of 40.63, a price-to-earnings-growth ratio of 3.08 and a beta of 0.31. The company has a current ratio of 1.93, a quick ratio of 1.40 and a debt-to-equity ratio of 0.03. The company’s 50-day moving average is $12.83 and its two-hundred day moving average is $13.26. Dr. Reddy’s Laboratories has a 12-month low of $11.36 and a 12-month high of $15.67.

Dr. Reddy’s Laboratories (NYSE:RDY) last posted its quarterly earnings data on Saturday, October 24th. The company reported $0.12 EPS for the quarter, topping analysts’ consensus estimates of $0.10 by $0.02. Dr. Reddy’s Laboratories had a return on equity of 7.91% and a net margin of 8.56%. The firm had revenue of $903.89 million during the quarter, compared to analysts’ expectations of $894.94 million.

Institutional Investors Weigh In On Dr. Reddy’s Laboratories

Institutional investors have recently bought and sold shares of the stock. Diversified Trust Co acquired a new position in Dr. Reddy’s Laboratories during the third quarter worth approximately $132,000. Allworth Financial LP boosted its holdings in shares of Dr. Reddy’s Laboratories by 34.1% in the 3rd quarter. Allworth Financial LP now owns 10,809 shares of the company’s stock valued at $136,000 after purchasing an additional 2,747 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Dr. Reddy’s Laboratories by 1,150.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 80,500 shares of the company’s stock valued at $1,016,000 after purchasing an additional 74,063 shares during the last quarter. Eurizon Capital SGR S.p.A. grew its stake in shares of Dr. Reddy’s Laboratories by 36.9% during the 3rd quarter. Eurizon Capital SGR S.p.A. now owns 23,864 shares of the company’s stock valued at $307,000 after buying an additional 6,430 shares during the period. Finally, Aikya Investment Management Ltd grew its stake in shares of Dr. Reddy’s Laboratories by 6.8% during the 3rd quarter. Aikya Investment Management Ltd now owns 9,068,536 shares of the company’s stock valued at $114,445,000 after buying an additional 574,684 shares during the period. 3.85% of the stock is currently owned by hedge funds and other institutional investors.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories is an India-based pharmaceutical company that develops, manufactures and markets generic medicines, active pharmaceutical ingredients (APIs) and other healthcare products. Its portfolio includes branded and unbranded generics, biosimilars and select proprietary medicines across therapeutic areas such as oncology, gastroenterology, cardiovascular care and diabetes.

Founded in 1984 by Kallam Anji Reddy, the company is headquartered in Hyderabad, India. It serves patients and customers in India and international markets, including the United States, Europe and countries in Russia and the Commonwealth of Independent States.

Dr.